Daktari Diagnostics has announced it has closed a $15.5 million series D round of funding.
Daktari, headquartered in Cambridge, Mass., is a developer of portable diagnostic products.
The funding round was led by new investors Eastern Capital Limited and the Merck Global Health Innovation Fund. Existing investors Norwich Ventures and Partners Innovation Fund also participated.
Daktari's CEO indicated the company's near-term goal is to create a menu of tests for major infectious diseases that can run on the Daktari CD4 diagnostic platform in 15-30 minutes.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
